Healthcare provider profile · identity verified

Rami Michael, MD

Internal Medicine · LA JOLLA, CA · NPI 1467871673

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	528	81
Metformin Hcl	Metformin Hcl	344	50
Amlodipine Besylate	Amlodipine Besylate	293	49
Gabapentin	Gabapentin	252	34
Lisinopril	Lisinopril	244	32
Levothyroxine Sodium	Levothyroxine Sodium	237	34
Losartan Potassium	Losartan Potassium	236	32
Rosuvastatin Calcium	Rosuvastatin Calcium	221	36
Famotidine	Famotidine	180	29
Carvedilol	Carvedilol	179	25
Simvastatin	Simvastatin	173	26
Tamsulosin Hcl	Tamsulosin Hcl	155	23
Omeprazole	Omeprazole	147	23
Jardiance	Empagliflozin	140	21
Metoprolol Succinate	Metoprolol Succinate	124	18
Hydrochlorothiazide	Hydrochlorothiazide	107	16
Eliquis	Apixaban	106	14
Pantoprazole Sodium	Pantoprazole Sodium	92	22
Januvia	Sitagliptin Phosphate	91	15
Alendronate Sodium	Alendronate Sodium	85	17
Albuterol Sulfate Hfa	Albuterol Sulfate	80	17
Ozempic	Semaglutide	74	suppressed
Fluticasone Propionate	Fluticasone Propionate	72	19
Montelukast Sodium	Montelukast Sodium	70	13
Janumet	Sitagliptin Phos/Metformin Hcl	69	suppressed
Trazodone Hcl	Trazodone Hcl	69	16
Clopidogrel	Clopidogrel Bisulfate	67	15
Metoprolol Tartrate	Metoprolol Tartrate	63	suppressed
Spironolactone	Spironolactone	61	11
Ezetimibe	Ezetimibe	55	suppressed
Glipizide	Glipizide	55	suppressed
Furosemide	Furosemide	53	12
Trulicity	Dulaglutide	51	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	50	suppressed
Ventolin Hfa	Albuterol Sulfate	49	suppressed
Ketoconazole	Ketoconazole	48	12
Pravastatin Sodium	Pravastatin Sodium	42	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	40	suppressed
Sertraline Hcl	Sertraline Hcl	39	suppressed
Duloxetine Hcl	Duloxetine Hcl	38	suppressed
Meloxicam	Meloxicam	38	suppressed
Myrbetriq	Mirabegron	38	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	36	suppressed
Nitroglycerin	Nitroglycerin	36	suppressed
Linzess	Linaclotide	34	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	34	suppressed
Allopurinol	Allopurinol	32	suppressed
Glipizide Er	Glipizide	32	suppressed
Hydralazine Hcl	Hydralazine Hcl	32	suppressed
Tramadol Hcl	Tramadol Hcl	32	suppressed
Metformin Er Gastric	Metformin Hcl	31	suppressed
Propranolol Hcl	Propranolol Hcl	31	suppressed
Ranolazine Er	Ranolazine	31	suppressed
Hydrocortisone	Hydrocortisone	30	suppressed
Ibuprofen	Ibuprofen	29	14
Mirtazapine	Mirtazapine	29	suppressed
Procto-Med Hc	Hydrocortisone	29	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	29	suppressed
Azelastine Hcl	Azelastine Hcl	28	suppressed
Metformin Hcl Er	Metformin Hcl	28	suppressed
Xarelto	Rivaroxaban	28	suppressed
Brilinta	Ticagrelor	27	suppressed
Entresto	Sacubitril/Valsartan	27	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	27	suppressed
Donepezil Hcl	Donepezil Hcl	26	suppressed
Farxiga	Dapagliflozin Propanediol	26	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	26	12
Celecoxib	Celecoxib	25	suppressed
Invokana	Canagliflozin	25	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	24	suppressed
Meclizine Hcl	Meclizine Hcl	24	suppressed
Naproxen	Naproxen	24	12
Gemfibrozil	Gemfibrozil	23	suppressed
Glimepiride	Glimepiride	23	suppressed
Valsartan	Valsartan	22	suppressed
Diclofenac Sodium	Diclofenac Sodium	21	suppressed
Nifedipine Er	Nifedipine	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Benazepril Hcl	Benazepril Hcl	19	suppressed
Clonidine Hcl	Clonidine Hcl	19	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Atenolol	Atenolol	17	suppressed
Tradjenta	Linagliptin	17	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	16	suppressed
Alprazolam	Alprazolam	15	suppressed
Colchicine	Colchicine	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Lidocaine	Lidocaine	14	suppressed
Metformin Er Osmotic	Metformin Hcl	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Azithromycin	Azithromycin	13	13
Baclofen	Baclofen	13	suppressed
Cephalexin	Cephalexin	13	suppressed
Cilostazol	Cilostazol	13	suppressed
Irbesartan	Irbesartan	13	suppressed
Nystatin	Nystatin	13	suppressed
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Jentadueto	Linagliptin/Metformin Hcl	12	suppressed
Memantine Hcl	Memantine Hcl	12	suppressed
Mesalamine Dr	Mesalamine	12	suppressed
Methimazole	Methimazole	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	12
Sildenafil Citrate	Sildenafil Citrate	12	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	11	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Finasteride	Finasteride	11	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Solifenacin Succinate	Solifenacin Succinate	11	suppressed
Sotalol	Sotalol Hcl	11	suppressed
Vascepa	Icosapent Ethyl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error